Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation Article (Faculty180)

cited authors

  • Sahloff, Eric G; Duggan, Joan M


  • Limited data exist on the use of a boosted protease inhibitor plus <2 active nucleoside/nucleotide reverse transcriptase inhibitors without use of additional classes of antiretroviral (ARV) therapy in treatment-experienced patients with background resistance.


publication date

  • 2019

published in

start page

  • 50

end page

  • 55


  • 53